See Our Winners, Runners Up & Shortlisted
The 2026 winners and runners-up were announced during a special ceremony taking place at the 17th World ADC San Diego.
Best ADC Platform Technology
Winner:
ConjuAll
LigaChem Biosciences
Runner Up:
GlycoConnect
Lonza
Shortlisted:
- AJICAP – Ajinomoto Bio-Pharma Services
- ConjuAll – LigaChem Biosciences
- GlycoConnect – Lonza
- TMALIN – MediLink Therapeutics
- WuXi DARx – WuXi XDC
Best New ADC Drug Developer
Winner:
Callio Therapeutics
Runner Up:
Kivu Bioscience
Shortlisted:
- Aarvik Therapeutics
- Callio Therapeutics
- Kivu Bioscience
- Valink Therapeutics
Most Promising ADC to Watch
Winner:
Mocertatug rezetecan (Mo-Rez)
GSK & Hansoh Pharma
Runner Up:
TUB-040
Gilead & Tubulis
Shortlisted:
- DS3939a - Daiichi Sankyo
- Emiltatug ledadotin (Emi-Le) - Servier
- JK06 - Salubris Biotherapeutics
- Mocertatug rezetecan (Mo-Rez) - GSK & Hansoh Pharma
- Puxitatug Samrotecan - AstraZeneca
- Sofetabart Mipitecan - Eli Lilly
- TUB-040 - Gilead & Tubulis
Best ADC Clinical Impact
Winner:
Izalontamab brengitecan (Iza-bren)
BMS & SystImmune
Runner Up:
HER3-DXd
Daiichi Sankyo & Merck
Shortlisted:
- Izalontamab brengitecan (Iza-bren) – BMS & SystImmune
- HER3-DXd – Daiichi Sankyo & Merck
- IKS014 – Iksuda Therapeutics & Fosun Pharma
Best CDMO
Winner:
WuXi XDC
Runner Up:
BSP Pharmaceuticals
Shortlisted:
- Abzena
- AsymBio
- Axplora
- BSP Pharmaceuticals
- Lonza
- MilliporeSigma
- Piramal Pharma Solutions
- WuXi XDC
Best CRO
Winner:
WuXi XDC
Runner Up:
NJ Bio
Shortlisted:
- Charles River Laboratories
- ChemExpress
- Crown Biosciences
- NJ Bio
- WuXi XDC
Best Up & Coming Solution Provider
Winner:
LIDE Biotech
Runner Up:
HUB Organoids
Shortlisted:
- HUB Organoids
- LIDE Biotech
- LOTTE Biologics
- Sygnature Discovery
- Turbine
- Xcellon Biologics
Best Clinical Publication 2025
Winner:
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01
Runner Up:
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Best Preclinical Publication 2025
Winner:
Effective Extracellular Payload Release and Immunomodulatory Interactions Govern the Therapeutic Effect of Trastuzumab Deruxtecan
Runner Up:
XMT-2056, a HER2-Directed STING Agonist ADC, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Best Poster 2026
Winner:
Defence Therapeutics
Outstanding Academic Investigator Award
Winner:
Edward Tate
Imperial College London
The George R. Pettit Individual Input to the Field 2025
Winner:
Dominik Schumacher
The Toshinori Agatsuma Long Standing Contribution to the Field Award
Explore World ADC San Diego's Agenda
Discover the latest industry breakthroughs and insights to be shared at the biggest ADC event, ahead of the awards' gala.
Partner With Us
Position yourself in front of the pioneers trailblazing ADCs to standard of care treatments.
View the 2026 Winners
Explore the 2026 winners recognised for their exceptional work in propelling the ADC field to new heights.